Floatz logo

Autologous Anti-Cd19/Cd20/Cd22 Car T-Cells

Recurrent Transformed Chronic Lymphocytic Leukemia

Ohio State University Comprehensive Cancer CenterCell therapyPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

15 Active assets in the Recurrent Transformed Chronic Lymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
SWOG Cancer Research Network
Phase 3BB
VINCRISTINE SULFATE
City of Hope Medical Center
Phase 2/3BB
Fludarabine
Ohio State University Comprehensive Cancer Center
Phase 2B
Zanubrutinib
City of Hope Medical Center
Phase 2B
Zofran
Mayo Clinic
Phase 2B

View all 15 →

Same molecule, other indications

Autologous Anti-Cd19/Cd20/Cd22 Car T-Cells is also rated in:

Recurrent Acute Lymphoblastic LeukemiaDormant
CC
Indicative ·
43 / 100
View asset →
Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 PositiveDormant
CC
Indicative ·
43 / 100
View asset →
Recurrent Chronic Myeloid Leukemia, BCR-ABL1 PositiveDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →